<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05064215</url>
  </required_header>
  <id_info>
    <org_study_id>EK 21-102-VK</org_study_id>
    <nct_id>NCT05064215</nct_id>
  </id_info>
  <brief_title>Lymphatic Drainage of the Breast, a Retrospective Assessment of Data</brief_title>
  <official_title>Lymphatic Drainage of the Breast, a Retrospective Assessment of Data</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Elisabeth Würinger</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wilhelminenspital Vienna</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      retrospective evaluation of patients, in whom blue colour was injected into different sites&#xD;
      of the breast before breast reduction, to investigate direction and localisation of lymphatic&#xD;
      flow. Investigations were performed at the Wilhelminenspital, Vienna, in the years 1998 to&#xD;
      2009.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 25, 2021</start_date>
  <completion_date type="Actual">August 10, 2021</completion_date>
  <primary_completion_date type="Actual">July 10, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Lymphatic flow is guided by the ligamentous suspension</measure>
    <time_frame>The ligamentous suspension (horizontal septum, vertical ligaments merging into superficial fascia) is exposed in the course of breast reduction in the technique, that I described usually within about 40 minutes</time_frame>
    <description>colour gathered along horizontal septum</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">14</enrollment>
  <condition>Lymph Drainage of Breast</condition>
  <arm_group>
    <arm_group_label>injection behind NAC</arm_group_label>
    <description>in 7 breasts dye was injected behind the nipple areola complex before breast reduction</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Injection into lateral upper quadrant</arm_group_label>
    <description>in 5 breasts dye was injected into upper lateral glandular tissue before breast reduction</description>
  </arm_group>
  <arm_group>
    <arm_group_label>injection into medial upper quadrant</arm_group_label>
    <description>in 2 breasts dye was injected into upper medial glandular tissue before breast reduction</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>anatomical examination</intervention_name>
    <description>After injection of dye, its distribution along lymphatic clearance paths was investigated</description>
    <arm_group_label>Injection into lateral upper quadrant</arm_group_label>
    <arm_group_label>injection behind NAC</arm_group_label>
    <arm_group_label>injection into medial upper quadrant</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients, who were operated on breast reduction&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria: Patients, who understood and supported the aim of the study and signed&#xD;
        the written consent -&#xD;
&#xD;
        Exclusion Criteria: language barriers, patients, who did not understand and support the aim&#xD;
        of the study&#xD;
&#xD;
        -&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Elisabeth Würinger</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dr. Elisabeth Würinger</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Elisabeth Wuringer</name>
      <address>
        <city>Wien</city>
        <state>Österreich</state>
        <zip>1130</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 24, 2021</study_first_submitted>
  <study_first_submitted_qc>September 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 1, 2021</study_first_posted>
  <last_update_submitted>September 21, 2021</last_update_submitted>
  <last_update_submitted_qc>September 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Wilhelminenspital Vienna</investigator_affiliation>
    <investigator_full_name>Dr. Elisabeth Würinger</investigator_full_name>
    <investigator_title>Dr. Elisabeth Würinger</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

